Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.

Prevymis (letermovir) - Merck (MSD)

cyclophosphamide - Generic mfg.

Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. (PubMed, Bone Marrow Transplant) - Jul 6, 2025 - No abstract available
Journal • Cytomegalovirus Infection • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/40617898

Abu-Sayeef Mirza; Aleksandr Lazaryan; Aliyah Baluch; Asmita Mishra; Biwei Cao; Claudio Anasetti; Eric Gaskill; Farhad Khimani; Hany Elmariah; Hien Liu; Jena Schmitz; Jongphil Kim; Jose L Ochoa-Bayona; Joseph A Pidala; Lia Perez; Michael Nieder; Nelli Bejanyan; Olga Klinkova; Rawan Faramand; Samantha Price; Taiga Nishihori

Jul 6, 2025